Epistemonikos summaries

← vista completa

Published on December 12, 2014 | http://doi.org/10.5867/medwave.2014.11.6052

Does preoperative intravitreal bevacizumab reduce complications of vitrectomy for proliferative diabetic retinopathy?

¿El uso preoperatorio de bevacizumab reduce las complicaciones en pacientes con retinopatía diabética sometidos a vitrectomía?

Daniela Véliz , Gabriel Rada

Abstract

Proliferative diabetic retinopathy carries a high risk of blindness if it is not timely treated. The treatment many times includes vitrectomy. Bevacizumab, an anti-vascular endothelial growth factor, may decrease intraoperative complications. Searching in Epistemonikos database, which is maintained by screening 20 databases, we identified three systematic reviews including 9 randomized trials. We combined the evidence using meta-analysis and generated a summary of findings table following the GRADE approach. We concluded that bevacizumab probably decreases time and intraoperative bleeding, but there is uncertainty regarding its effects on visual acuity, and it might increase the risk of cardiovascular events.

This work is licensed under a Creative Commons Attribution 4.0 International License. Esta licencia permite el uso, distribución y reproducción del artículo en cualquier medio, siempre y cuando se otorgue el crédito correspondiente al autor del artículo y al medio en que se publica, en este caso, Medwave.

Authors

Daniela Véliz

Programa de Salud Basada en Evidencia, Facultad de Medicina, Pontificia Universidad Católica de Chile, Santiago, Chile

radagabriel@epistemonikos.org.

Facultad de Medicina, Pontificia Universidad Católica de Chile, Lira 63, Santiago Centro, Chile

Gabriel Rada

Figures

Article has no figures.

Forum

No messages

History

Citation Véliz D, Rada G. Does preoperative intravitreal bevacizumab reduce complications of vitrectomy for proliferative diabetic retinopathy?. Medwave 2014;14(11):e6052 doi: 10.5867/medwave.2014.11.6052

Submission date 01/01/1970

Acceptance date 01/01/1970

Publication date 12/12/2014

Index

Metrics

Not available at the moment.

Notes

References

  1. Jonathan MS, David HWS. Anti-vascular endothelial growth factor for prevention of postoperative vitreous cavity haemorrhage after vitrectomy for proliferative diabetic retinopathy. Cochrane Database of Systematic Reviews. 2011 2011(5):CD008214. | Link
  2. Zhang ZH, Liu HY, Hernandez-Da Mota SE, Romano MR, Falavarjani KG, Ahmadieh H, et al. Vitrectomy with or without preoperative intravitreal bevacizumab for proliferative diabetic retinopathy: a meta-analysis of randomized controlled trials. Am J Ophthalmol. 2013 Jul;156(1):106-115.e2. | CrossRef | PubMed
  3. Zhao LQ, Zhu H, Zhao PQ, Hu YQ. A systematic review and meta-analysis of clinical outcomes of vitrectomy with or without intravitreal bevacizumab pretreatment for severe diabetic retinopathy. Br J Ophthalmol. 2011 Sep;95(9):1216-22. | CrossRef | PubMed
  4. Ahmadieh H, Shoeibi N, Entezari M, Monshizadeh R. Intravitreal bevacizumab for prevention of early postvitrectomy hemorrhage in diabetic patients: a randomized clinical trial. Ophthalmology. 2009 Oct;116(10):1943-8. | CrossRef | PubMed
  5. Ahn J, Woo SJ, Chung H, Park KH. The effect of adjunctive intravitreal bevacizumab for preventing postvitrectomy hemorrhage in proliferative diabetic retinopathy. Ophthalmology. 2011 Nov;118(11):2218-26. | CrossRef | PubMed
  6. da R Lucena D, Ribeiro JA, Costa RA, Barbosa JC, Scott IU, de Figueiredo-Pontes LL, et al. Intraoperative bleeding during vitrectomy for diabetic tractional retinal detachment with versus without preoperative intravitreal bevacizumab (IBeTra study). Br J Ophthalmol. 2009 May;93(5):688-91. | CrossRef | PubMed
  7. di Lauro R, De Ruggiero P, di Lauro R, di Lauro MT, Romano MR. Intravitreal bevacizumab for surgical treatment of severe proliferative diabetic retinopathy. Graefes Arch Clin Exp Ophthalmol. 2010 Jun;248(6):785-91. | CrossRef | PubMed
  8. El-Batarny AM. Intravitreal bevacizumab as an adjunctive therapy before diabetic vitrectomy. Clin Ophthalmol. 2008 Dec;2(4):709-16. | PubMed
  9. Farahvash MS1, Majidi AR, Roohipoor R, Ghassemi F. Preoperative injection of intravitreal bevacizumab in dense diabetic vitreous hemorrhage. Retina. 2011 Jul-Aug;31(7):1254-60. | CrossRef | PubMed
  10. Hernández-Da Mota SE, Nuñez-Solorio SM. Experience with intravitreal bevacizumab as a preoperative adjunct in 23-G vitrectomy for advanced proliferative diabetic retinopathy. Eur J Ophthalmol. 2010 Nov-Dec;20(6):1047-52. | PubMed
  11. Modarres M, Nazari H, Falavarjani KG, Naseripour M, Hashemi M, Parvaresh MM. Intravitreal injection of bevacizumab before vitrectomy for proliferative diabetic retinopathy. Eur J Ophthalmol. 2009 Sep-Oct;19(5):848-52. | PubMed
  12. Rizzo S, Genovesi-Ebert F, Di Bartolo E, Vento A, Miniaci S, Williams G. Injection of intravitreal bevacizumab (Avastin) as a preoperative adjunct before vitrectomy surgery in the treatment of severe proliferative diabetic retinopathy (PDR). Graefes Arch Clin Exp Ophthalmol. 2008 Jun;246(6):837-42. | CrossRef | PubMed
  13. Yang CM, Yeh PT, Yang CH, Chen MS. Bevacizumab pretreatment and long-acting gas infusion on vitreous clear-up after diabetic vitrectomy. Am J Ophthalmol. 2008 Aug;146(2):211-217. | CrossRef | PubMed
  14. Yeh PT, Yang CM, Lin YC, Chen MS, Yang CH. Bevacizumab pretreatment in vitrectomy with silicone oil for severe diabetic retinopathy. Retina. 2009 Jun;29(6):768-74. | CrossRef | PubMed
  15. Thulliez M, Angoulvant D, Le Lez ML, Jonville-Bera AP, Pisella PJ, Gueyffier F, et al. Cardiovascular events and bleeding risk associated with intravitreal antivascular endothelial growth factor monoclonal antibodies: systematic review and meta-analysis. JAMA Ophthalmol. 2014 Nov 1;132(11):1317-26. | CrossRef | PubMed
  16. Pareja-Ríos A, Serrano-García MA, Marrero-Saavedra MD, Abraldes-López VM, Reyes-Rodríguez MA, Cabrera-López F, et al. [Guidelines of clinical practice of the SERV (Spanish Retina and Vitreous Society): management of ocular complications of diabetes. Diabetic retinopathy and macular oedema]. Arch Soc Esp Oftalmol. 2009 Sep;84(9):429-50. | PubMed | Link
  17. Canadian Ophthalmological Society Diabetic Retinopathy Clinical Practice Guideline Expert Committee, Hooper P, Boucher MC, Cruess A, Dawson KG, Delpero W, et al. Canadian Ophthalmological Society Evidence-based Clinical Practice Guidelines for the Management of Diabetic Retinopathy - executive summary. Can J Ophthalmol. 2012 Apr;47(2):91-6. | CrossRef | PubMed
  18. Szabo SM, Beusterien KM, Pleil AM, Wirostko B, Potter MJ, Tildesley H, et al. Patient preferences for diabetic retinopathy health States. Invest Ophthalmol Vis Sci. 2010 Jul;51(7):3387-94. | CrossRef | PubMed
  19. Wirostko B1, Beusterien K, Grinspan J, Ciulla T, Gonder J, Barsdorf A, et al. Patient preferences in the treatment of diabetic retinopathy. Patient Prefer Adherence. 2011;5:229-37. | CrossRef | PubMed
  20. Manabe A. Prospective randomized controlled study of intravitreal injection of bevacizumab for proliferative diabetic retinopathy. 2013. clinicaltrials.gov [on line]. | Link
  21. Martinez-Zapata MJ, Martí-Carvajal AJ, Solà I, Pijoán JI, Buil-Calvo JA, Cordero JA, et al. Anti-vascular endothelial growth factor for proliferative diabetic retinopathy. Cochrane Database Syst Rev. 2014 Nov;11:CD008721. | CrossRef | PubMed
  22. Sohn EH, He S, Kim LA, Salehi-Had H, Javaheri M, Spee C, wt al. Angiofibrotic response to vascular endothelial growth factor inhibition in diabetic retinal detachment: report no. 1. Arch Ophthalmol. 2012 Sep;130(9):1127-34. | CrossRef | PubMed
  23. Zaman Y, Rehman AU, Memon AF. Intravitreal Avastin as an adjunct in patients with proliferative diabetic retinopathy undergoing pars plana vitrectomy. Pak J Med Sci. 2013 Apr;29(2):590-2. | PubMed | Link